This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E71.3 (Disorders of fatty-acid metabolism) | Special Copayment Reduction: V117 (ultra-rare disease, copayment exempt) |
| B. Synonyms | Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD), VLCAD deficiency, ACADVL deficiency, long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, LCHAD deficiency, HADHA deficiency, trifunctional protein deficiency (TFP) |
| C. Adult onset | Possibility of first manifestation in adulthood: not low — Mild VLCAD (muscular form) may first manifest in adults with myalgia and rhabdomyolysis after exercise. LCHAD deficiency mainly manifests in infancy, but there are also mild cases not diagnosed until adulthood in the era before newborn screening. In pregnant carriers of LCHAD, acute fatty liver of pregnancy (AFLP) can occur during pregnancy, which is clinically important in adult women. |
| 1. History | 1993 description of the VLCAD enzyme by Yamaguchi et al. → 1995 cloning of the ACADVL gene → 1989 report of LCHAD → 1990s cloning of the HADHA gene → association of LCHAD with maternal pregnancy complications (AFLP) confirmed. |
| 2. Causes | VLCAD: variants in the ACADVL gene (17p13.1) → deficiency of mitochondrial very long-chain acyl-CoA dehydrogenase. LCHAD: variants in the HADHA gene (2p23) → loss of LCHAD enzyme activity of the trifunctional protein (TFP). |
| 3. Genetics | Autosomal recessive. ACADVL: 17p13.1. HADHA: 2p23.3. The common LCHAD variant p.Glu474Gln (c.1528G>C) is found in about 90% of those of European descent. VLCAD variants are diverse and show genotype-phenotype correlation. |
| 4. General epidemiology | VLCAD incidence: 1:30,000-100,000 births. LCHAD: 1:113,000-250,000. Both occur worldwide. Frequency data are limited for Asia, including Korea. |
| 5. Pathophysiology | VLCAD: blockade of dehydrogenation of C14-C20 long-chain acyl-CoA → accumulation of long-chain acylcarnitines → hypoketotic hypoglycemia, cardiotoxicity. LCHAD: deficient LCHAD activity within the trifunctional protein → accumulation of 3-hydroxyacylcarnitines → neuropathy and retinopathy. |
| 6. Symptoms | Severe VLCAD: neonatal cardiomyopathy, hypoglycemia, hepatomegaly. Mild: muscular form with exercise intolerance and rhabdomyolysis. LCHAD: hypoketotic hypoglycemia, cardiomyopathy, neuropathy, pigmentary retinopathy. Pregnant carriers: AFLP and HELLP syndrome. |
| 7. Signs | Elevated plasma C14:1, C14:0, C16, and C18 acylcarnitines (VLCAD). LCHAD: elevated hydroxyacylcarnitines such as C16-OH and C18:1-OH. Hypoketotic hypoglycemia. Cardiomyopathy findings. |
| 8. Screening | Newborn MS/MS: for VLCAD, elevated C14:1 is the main marker. For LCHAD, elevated hydroxyacylcarnitines C16:0-OH and C18:1-OH. Values may normalize on a second screen, so confirmatory testing is needed immediately after the first positive result. |
| 9. Diagnosis | Plasma acylcarnitine analysis + urine organic acids + ACADVL or HADHA gene analysis. Enzyme activity (fibroblasts). Echocardiography (evaluation of cardiomyopathy). Ophthalmologic examination (follow-up of LCHAD retinopathy). |
| 10. Treatment | Avoidance of fasting, long-chain fatty acid-restricted diet, MCT oil supplementation. Intravenous glucose in the acute phase. LCHAD: DHA (docosahexaenoic acid) supplementation may delay retinopathy. Selective carnitine supplementation. |
| 11. Prognosis | Severe VLCAD: cardiomyopathy can be reversible with early treatment. Mild: normal life by avoiding triggers. LCHAD: neuropathy and retinopathy are progressive and affect long-term prognosis. Adherence to dietary treatment determines prognosis. |
| 12. Prevention | Newborn screening, genetic counseling, emergency plan, education on a long-chain fatty acid-restricted diet, monitoring of pregnant LCHAD carriers (awareness of AFLP risk), regular ophthalmologic examination (LCHAD). |
| 13. References | Spiekerkoetter U et al. J Inherit Metab Dis. 2010 (PMID 20532806) … and 9 other papers |
Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency came to be recognized as an independent disease in 1993, when Yamaguchi et al. first described, in patients with a long-chain fatty acid oxidation disorder, a new enzyme deficiency distinct from the previously known LCAD (long-chain acyl-CoA dehydrogenase). VLCAD is an inner mitochondrial membrane-bound enzyme that uses C14-C20 long-chain acyl-CoA as substrates, and subsequent reevaluation showed that many patients previously classified as having LCAD deficiency actually had VLCAD deficiency. The ACADVL gene was cloned in 1995, making molecular diagnosis possible.
Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency was first reported by Bhatt et al. in 1989. LCHAD is located on the alpha subunit (encoded by HADHA) of the trifunctional protein (TFP) of the inner mitochondrial membrane and catalyzes the 3-hydroxyacyl-CoA dehydrogenation reaction, the third step of beta-oxidation. TFP is a complex that has all three enzyme activities, enoyl-CoA hydratase, LCHAD, and 3-ketoacyl-CoA thiolase; variants in the HADHA or HADHB gene cause either complete TFP deficiency or selective LCHAD deficiency.
A clinically important finding in LCHAD deficiency is that acute fatty liver of pregnancy (AFLP) and HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) are markedly increased in heterozygous (carrier) mothers carrying a fetus with LCHAD deficiency. This association was first reported by Treem et al. in 1994, and is explained by excess hydroxyacylcarnitines from the LCHAD-deficient fetus being transferred to the mother across the placenta and causing hepatotoxicity. This finding highlighted the importance of newborn screening for LCHAD deficiency in mothers with AFLP or HELLP.
VLCAD deficiency: Caused by reduced or lost mitochondrial very long-chain acyl-CoA dehydrogenase (VLCAD) activity due to pathogenic variants in the ACADVL gene (short arm of chromosome 17, 17p13.1). VLCAD is an enzyme with a homodimer structure bound to the inner mitochondrial membrane that, with FAD as a cofactor, catalyzes the first dehydrogenation step of long-chain acyl-CoAs of 14-20 carbons. In VLCAD deficiency, beta-oxidation of C14-C20 long-chain fatty acids is blocked and toxic long-chain acylcarnitines (especially C14:1-carnitine, tetradecenoylcarnitine) accumulate in the blood. These toxic acylcarnitines disturb cardiac ion channels and the electron transport chain, causing arrhythmia and myocardial dysfunction.
LCHAD deficiency: Caused by damage to the mitochondrial trifunctional protein alpha subunit of the mitochondrial trifunctional protein (TFP) due to pathogenic variants in the HADHA gene (short arm of chromosome 2, 2p23.3). TFP is an alpha4-beta4 heterooctamer composed of alpha (encoded by HADHA) and beta (encoded by HADHB) subunits, bound to the inner mitochondrial membrane, and sequentially performs the three steps of long-chain fatty acid beta-oxidation (hydration, 3-hydroxyacyl-CoA dehydrogenation, thiolysis). Selective LCHAD deficiency is mainly caused by a specific variant of the HADHA gene (c.1528G>C, p.Glu474Gln), and complete TFP deficiency is due to complete loss-of-function variants of HADHA or HADHB. In LCHAD deficiency, long-chain 3-hydroxyacyl-CoA and 3-hydroxyacylcarnitines accumulate, and these toxic metabolites are toxic to the retina, peripheral nerves, liver, and heart.
Both diseases follow an autosomal recessive mode of inheritance. The ACADVL gene is located on the short arm of chromosome 17 (17p13.1) and consists of about 5.4 kb and 20 exons. The encoded VLCAD precursor is 655 amino acids. More than 200 pathogenic ACADVL variants have been reported, including missense, nonsense, deletion, insertion, and splicing variants. There is some correlation between variant type and phenotype: loss-of-function variants (nonsense, frameshift) tend to be associated with the severe cardiomyopathy form, and missense variants (especially those with residual enzyme activity) with the mild muscular form.
The HADHA gene is located on the short arm of chromosome 2 (2p23.3) and consists of about 58 kb and 20 exons. The most common variant associated with selective LCHAD deficiency is c.1528G>C (p.Glu474Gln), which is found in at least one allele in about 80-90% of LCHAD-deficient patients of European descent. This variant changes a key residue at the LCHAD active site within the TFP complex, causing selective loss of LCHAD activity. In patients of Asian descent, including Korea, the frequency of c.1528G>C is low and various rare variants have been reported. Variants in the HADHB gene (2p23.3) cause complete TFP deficiency and tend to be more severe than LCHAD deficiency. Molecular diagnosis is performed by NGS panel, WES, and WGS, and prenatal diagnosis and PGT are possible when a family history is confirmed.
The overall incidence of VLCAD deficiency is estimated, based on newborn screening data, at about 1 in 30,000-100,000 births. It varies by region: 1 in 40,000-50,000 births in Europe, and higher frequencies have been reported in some Middle Eastern regions. Newborn screening studies in Sweden reported about 1 in 85,000 births, and Italy 1 in 65,000. Since the introduction of MS/MS newborn screening, the diagnosis rate of VLCAD has increased greatly, and a high frequency of about 1 in 7,300 births has been reported in Kuwait, showing regional differences.
The incidence of LCHAD deficiency is lower than that of VLCAD, estimated at about 1 in 113,000-250,000 births. In Finland, a relatively high frequency of about 1 in 60,000 births has been reported owing to the founder effect of the c.1528G>C variant. There is no sex difference, and it occurs in all races worldwide. Precise epidemiological data in Korea are limited, but diagnosed cases of both diseases have been increasing since the expansion of newborn screening. A notable point in VLCAD deficiency is that many of the patients identified by newborn screening are clinically asymptomatic or have a mild phenotype, because screening programs capture more mild variants.
The pathophysiology of VLCAD deficiency is explained by two main mechanisms. First, energy deficiency due to blockade of long-chain fatty acid oxidation. VLCAD is the key enzyme that catalyzes the first dehydrogenation reaction of C14-C20 acyl-CoAs in the mitochondrial beta-oxidation spiral. In VLCAD deficiency, long-chain fatty acids in this substrate range cannot enter beta-oxidation, so the energy supply to the heart, skeletal muscle, and liver is blocked. Energy deficiency becomes more pronounced during fasting, fever, and exercise. Second, accumulation of toxic acylcarnitines (long-chain acylcarnitines, especially C14:1-carnitine, C14:0-carnitine, C16:0-carnitine). These toxic metabolites disturb ion channels (especially calcium channels) of cardiomyocytes and inhibit the mitochondrial electron transport chain, causing myocardial dysfunction and arrhythmia. Cardiomyopathy and arrhythmia are the most dangerous complications of severe neonatal VLCAD.
The pathophysiology of LCHAD deficiency is similar to that of VLCAD but has an additional specific mechanism. 3-Hydroxyacyl-CoAs (especially 3-hydroxypalmitoyl-CoA, 3-hydroxyoleoyl-CoA) and the corresponding hydroxyacylcarnitines (3-hydroxyacylcarnitines) accumulate. These hydroxy metabolites are strongly cytotoxic and are directly toxic especially to retinal pigment epithelium (RPE) cells, peripheral nerve cells, and hepatocytes. Pigmentary retinopathy and peripheral neuropathy are long-term complications characteristic of LCHAD deficiency and are uncommon findings in VLCAD deficiency. AFLP/HELLP syndrome in pregnant LCHAD carriers is explained by excess hydroxyacylcarnitines from the fetus exerting a toxic effect on the maternal liver through placental blood flow.
Clinical phenotypes of VLCAD deficiency: There are three main phenotypes. (1) Severe neonatal/infantile form: characterized by hypertrophic cardiomyopathy, cardiac arrhythmia, hypoketotic hypoglycemia, and hepatomegaly occurring in the neonatal period or within a few months of birth. Fasting without dietary control can rapidly lead to heart failure and sudden death. Cardiomyopathy often improves reversibly once appropriate treatment (avoidance of fasting, long-chain FA-restricted diet) is started. (2) Infantile/childhood form: hypoglycemia, hepatomegaly, liver dysfunction, and hypotonia occur with fever or infection, but cardiac involvement is less common. (3) Muscular form (mild, adult form): manifests as myalgia after exercise or fasting, exercise intolerance, and rhabdomyolysis. The age at onset varies from adolescence to adulthood. There is no or only mild cardiac involvement.
Clinical symptoms of LCHAD deficiency: The main age at onset is infancy (several months of age to 2 years), and typical symptoms are hypoketotic hypoglycemia triggered by fever or fasting, hepatomegaly, and liver dysfunction. Cardiomyopathy is less frequent than in VLCAD but accompanies the disease in some patients. Complications characteristic of LCHAD deficiency include pigmentary retinopathy and peripheral neuropathy. These complications progressively worsen over time and can cause severe visual impairment and gait disturbance in adulthood. Carrier mothers carrying a fetus with LCHAD deficiency have a significantly higher risk of acute fatty liver of pregnancy (AFLP) or HELLP syndrome in the third trimester.
Biochemical signs of VLCAD deficiency: On plasma acylcarnitine analysis, a marked elevation of tetradecenoylcarnitine (C14:1-carnitine) is the most specific marker. C14:0 and C16:0 acylcarnitines are also elevated. The C14:1/C2 ratio is used to improve diagnostic sensitivity and specificity. Urine organic acids may show a mild increase in dicarboxylic acids. In the acute phase, hypoketotic hypoglycemia, elevated CK (muscular form), elevated AST and ALT (hepatic form), and elevated cardiac enzymes (troponin, BNP) (cardiac form) appear. Echocardiography shows myocardial hypertrophy or reduced ventricular function.
Biochemical signs of LCHAD deficiency: Characterized by elevated hydroxyacylcarnitines such as 3-hydroxypalmitoylcarnitine (C16:0-OH) and 3-hydroxyoleoylcarnitine (C18:1-OH) on plasma acylcarnitine analysis. 3-Hydroxydicarboxylic acids are excreted in urine organic acids. In the acute phase, hypoketotic hypoglycemia, elevated AST and ALT, and hyperammonemia appear, similar to VLCAD. Ophthalmologic examination shows pigmentary retinopathy (retinal pigment epithelium degeneration, choroidal atrophy). Nerve conduction studies show a sensorimotor neuropathy pattern. In pregnant women carrying a fetus with LCHAD deficiency, thrombocytopenia, elevated liver enzymes (ALT, AST), and elevated LDH may appear as signs of AFLP/HELLP.
Both VLCAD and LCHAD deficiency are included in tandem mass spectrometry (MS/MS)-based newborn screening. The main screening marker for VLCAD deficiency is elevated plasma C14:1 (tetradecenoylcarnitine). C14:1 and the C14:1/C2 ratio are used as the first-tier indicators for VLCAD screening, and elevated C14:0 and C16:0 are secondary indicators. When elevated C14:1 is found in a newborn, repeat plasma acylcarnitine analysis, urine organic acids, and ACADVL gene testing are performed immediately. However, C14:1 may normalize on a second screening test, so confirmatory testing must be performed immediately when the first screen is positive.
The screening markers for LCHAD deficiency are elevated C16:0-OH (3-hydroxypalmitoylcarnitine) and C18:1-OH (3-hydroxyoleoylcarnitine). Gene analysis is needed to distinguish LCHAD from complete TFP deficiency. In many countries, including Korea, VLCAD and LCHAD deficiency are included in expanded newborn screening. As prenatal testing, when AFLP or HELLP syndrome has occurred in a pregnant woman, HADHA gene analysis in the newborn is recommended to determine whether LCHAD deficiency is present. Carrier testing of family members and prenatal diagnosis (CVS, amniocentesis) can also be used in at-risk groups.
Definitive diagnosis of VLCAD and LCHAD deficiency is made by a combination of biochemical testing, molecular genetic testing, and, when necessary, enzyme testing. Plasma acylcarnitine analysis: VLCAD shows elevated C14:1, C14:0, and C16:0. LCHAD shows elevated hydroxyacylcarnitines C16:0-OH and C18:1-OH. Specimens from the acute phase show the most obvious abnormalities and may normalize during the intermittent phase, so freezing and storing blood and urine specimens from the acute phase is important. Urine organic acids: VLCAD shows increased dicarboxylic acids. LCHAD shows increased 3-hydroxydicarboxylic acids. ACADVL or HADHA/HADHB gene analysis: pathogenic variants are confirmed by NGS panel, WES, and WGS. Confirmation of c.1528G>C homozygosity is sufficient for definitive diagnosis of selective LCHAD deficiency.
Enzyme activity measurement: VLCAD or LCHAD enzyme activity is measured in cultured skin fibroblasts. Enzyme activity below 10% of normal controls is diagnostic. TFP deficiency can also be confirmed. Echocardiography: evaluation of myocardial hypertrophy, left ventricular function, and ejection fraction. Essential for diagnosing severe neonatal VLCAD and monitoring treatment response. Ophthalmologic examination: performed immediately after diagnosis of LCHAD deficiency; the baseline state of pigmentary retinopathy is documented and then followed at 6-12-month intervals. Fluorescein angiography (FAG) and ERG (electroretinography) are useful for evaluating the extent of the lesion. Neurological testing: peripheral neuropathy is quantitatively evaluated by nerve conduction studies.
Treatment of VLCAD and LCHAD deficiency centers on a long-chain fatty acid-restricted diet, MCT oil supplementation, and avoidance of fasting. In these two diseases, long-chain fatty acids are direct precursors of toxic metabolites, so, unlike MCADD, MCT oil (medium-chain triglycerides with 8-10 carbons) is actively used as an alternative energy source.
Dietary treatment: Long-chain fatty acid (LCT, long-chain triglycerides) intake is restricted to 10-15% or less of total energy, and MCT oil is supplemented at 15-20% of total energy. However, a minimum amount of essential fatty acids (linoleic acid, alpha-linolenic acid) must be supplied, so complete restriction of long-chain fat is not possible. Energy is supplied sufficiently with carbohydrates and protein. For infants, a special formula with restricted long-chain fat (MCT-enriched formula) is used. Avoidance of fasting: as with MCADD, observe the age-appropriate maximum fasting time and follow the emergency glucose supplementation protocol during infection or fever.
LCHAD deficiency-specific treatment: Small studies suggest that docosahexaenoic acid (DHA) supplementation may slow the progression of retinopathy. DHA is an essential omega-3 fatty acid that is easily deficient on a long-chain fatty acid-restricted diet, so supplementation is recommended. For progression of pigmentary retinopathy, there is no proven treatment to date other than regular ophthalmologic follow-up. Acute-phase treatment: intravenous 10% glucose fluids suppress protein catabolism and supply energy. When myocardial dysfunction is present, appropriate heart failure treatment is needed. Carnitine may be used selectively to eliminate toxic acylcarnitines from the blood, but because long-chain acylcarnitines are cardiotoxic, indiscriminate high-dose carnitine administration should be approached with caution.
Prognosis of VLCAD deficiency: In the severe neonatal form, when cardiomyopathy is diagnosed early and dietary treatment is started, the cardiomyopathy often improves reversibly. In patients diagnosed early by newborn screening who adhere to avoidance of fasting and a long-chain FA-restricted diet, normal development and good quality of life are possible. Patients with the muscular form (mild) can live near-normal lives if they avoid triggers. In patients with delayed diagnosis in the era before newborn screening, the risk of acute heart failure, brain damage, and death was high. On long-term follow-up, some patients experience episodes of intermittent metabolic crisis, and decreased renal function after rhabdomyolysis can be a problem.
Prognosis of LCHAD deficiency: Hypoglycemia, liver crisis, and cardiac function can be controlled with appropriate dietary treatment, but pigmentary retinopathy and peripheral neuropathy progress slowly over time. Retinopathy can lead to severe visual impairment in adulthood and has an important effect on long-term prognosis. There is limited evidence that DHA supplementation can slow the progression of retinopathy, but complete prevention is difficult. Adherence to dietary treatment and prevention of metabolic crises are the most important factors in the long-term prognosis of LCHAD. When AFLP/HELLP occurs in a pregnant LCHAD carrier, early delivery and aggressive management are essential to reduce maternal and fetal mortality.
Early diagnosis through newborn screening (MS/MS acylcarnitine analysis; C14:1 marker for VLCAD, C16:0-OH marker for LCHAD) is the core of primary prevention. Newborns with a positive screen are referred immediately to a specialized metabolic disease center for confirmatory testing and establishment of a dietary treatment plan. When there is a family history, carrier status confirmation, prenatal diagnosis, and PGT are used.
Secondary prevention in confirmed patients includes dietary management education, carrying an emergency protocol card, and metabolic consultation before surgery or anesthesia. Avoidance of fasting and continued adherence to a long-chain FA-restricted diet are the key to preventing metabolic crises. Patients with the VLCAD muscular form adjust exercise intensity and duration, consume sufficient carbohydrates before prolonged exercise, and regularly replenish fluids and carbohydrates during exercise. For patients with LCHAD deficiency, an ophthalmologic examination is performed immediately at diagnosis for early detection of retinopathy and then followed at 6-12-month intervals. DHA supplementation is started early. A heterozygous mother carrying a fetus with LCHAD deficiency informs the obstetrician in advance of the risk of AFLP and HELLP in the third trimester, and active monitoring is carried out.